Alder to present new data for Eptinezumab at American Headache Society Meeting

Alder BioPharmaceuticals announced that it will present updated data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, Alder’s lead investigational product candidate for migraine prevention, at the upcoming American Headache Society (AHS) annual scientific meeting at the Marriott Marquis in San Francisco, CA (June 28 – July 1, 2018).

Eptinezumab data will be presented in multiple late-breaking sessions, platform presentations and poster presentations, and will debut efficacy data from PROMISE 2 for chronic migraine patients who received two quarterly infusions of eptinezumab. Key outcomes from PROMISE 2 will include monthly migraine days, early onset of activity and responder rates (≥50, ≥75 and 100 percent) after two quarterly infusions. The presentations also will include new year-long data from PROMISE 1 evaluating eptinezumab in episodic migraine patients, as well as outcomes of the Short-Form Health Survey Scores in PROMISE 2, which assess quality of life.

“At Alder, we are committed to advancing the treatment paradigm for migraine prevention for patients whose quality-of-life is severely impacted by this debilitating condition,” said Robert Azelby, chief executive officer of Alder. “Our new and compelling efficacy and outcomes data showing a large percentage of patients achieving Day One reductions in migraine risk that is sustained through 12 weeks and also further improves after two or more quarterly infusions, continues to support eptinezumab’s potential to be a meaningful, new treatment option for migraine patients.”

Late-Breaking Studies, Friday, June 29:

Session PF110LB: Display: 6:30 am – 5:00 pm PT; Presentation: 1:15 pm – 2:15 pm PT, Yerba Buena Ballroom

• Eptinezumab for Prevention of Chronic Migraine (CM): Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy‒2) Trial
  • Presenter: Dr. Richard Lipton, director, Montefiore Headache Center, Albert Einstein College of Medicine

Session PF108LB: Display: 6:30 am – 5:00 pm PT; Presentation: 1:15 pm – 2:15 pm PT, Yerba Buena Ballroom

• Eptinezumab Results for the Prevention of Episodic Migraine Over One Year in the PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy‒1) Trial
  • Presenter: Dr. Stephen Silberstein, professor of neurology and director of the Jefferson Headache Center, Thomas Jefferson University

Platform Presentations, Saturday, June 30:

Session IOR03: 8:20 am – 8:30 am PT, Yerba Buena Ballroom

• Eptinezumab Reduced Migraine Activity and Achieved High Migraine Responder Rates over Weeks 1‒12: Results from the Phase 3 PROMISE-2 Trial in Chronic Migraine
  • Presenter: Dr. Paul Winner, director of both the Premiere Research Institute and the Palm Beach Headache Center in West Palm Beach, FL

Session IOR04: 8:30 am – 8:40 am PT, Yerba Buena Ballroom

• Eptinezumab Achieved Meaningful Reductions in Migraine Activity as Early as Day 1: PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine
  • Presenter: Dr. Roger Cady, vice president of neurology, Alder BioPharmaceuticals and fellow, American Headache Society

Poster Presentations:

All posters displayed Friday, June 29, 6:30 am – 5:00 pm PT; Presentations: 1:15 pm – 2:15 pm PT, Yerba Buena Ballroom

• PF06: Migraine Activity Reductions with Eptinezumab Were Associated with Improvements in Short-Form Health Survey Scores Most Affected by Migraine: Results from Phase 3 PROMISE-2 Trial in Chronic Migraine
  • Presenter: Dr. Joel Saper, founder and director, Michigan Headache and Neurology Institute
• PF34: Baseline Population Characteristics of PROMISE-2: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Eptinezumab for Prevention of Chronic Migraine
  • Presenter: Dr. Egilius Spierings, director and principal investigator, MedVadis Research Corporation
• PF10: Eptinezumab Reduced Migraine Hours and Severity, Which Were Accompanied by Improved HIT-6 Scores, over Weeks 1‒12: Results from the Phase 3 PROMISE-2 Trial in Chronic Migraine
  • Presenter: Dr. Timothy Smith, medical director, Mercy Health Research, Mercy Medical Group
• PF02: A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE 2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy‒2) Trial
  • Presenter: Dr. Richard Lipton, director, Montefiore Headache Center, Albert Einstein College of Medicine
• PF20: Eptinezumab Reduced Migraine Frequency and Triptan/Ergotamine Use Over Weeks 1‒12, and Improved HIT-6 Scores at Months One and Three: Results From the Phase 3 PROMISE-2 Trial in Chronic Migraine
  • Presenter: Dr. Stephen Silberstein, professor of neurology and director, Jefferson Headache Center, Thomas Jefferson University

E-Poster Presentations:

All e-posters displayed Friday, June 29, 1:55 pm – 2:00 pm PT; Exhibit Hall

• Room 3: Eptinezumab Reduced Migraine Hours and Severity, Which Were Accompanied by Improved HIT-6 Scores, over Weeks 1‒12: Results from the Phase 3 PROMISE-2 Trial in Chronic Migraine
  • Presenter: Dr. Timothy Smith, medical director, Mercy Health Research, Mercy Medical Group
• Room 2: A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy‒2) Trial
  • Presenter: Dr. Richard Lipton, director, Montefiore Headache Center, Albert Einstein College of Medicine

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/

News Source: Alder website

Image Source: http://www.yourdictionary.com/scientific-data